期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗体依赖细胞介导的细胞毒作用在利妥昔单抗耐药机制中的研究进展

Research advances of antibody-dependent cell-mediated cytotoxicity in the resistance of rituximab
原文传递
导出
摘要 利妥昔单抗是一种在B细胞非霍奇金淋巴瘤（B-NHL）中广泛应用的单抗类靶向药物,作用于CD20抗原.其联合化疗显著改善了B细胞淋巴瘤患者的预后.但是仍有部分患者对利妥昔单抗治疗无效或在治疗有效后短期内复发,提示可能存在利妥昔单抗的耐药.利妥昔单抗对B细胞淋巴瘤细胞的杀伤机制主要包括直接诱导凋亡、抗体依赖细胞介导的细胞毒作用（ADCC）、补体依赖细胞毒作用（CDC）等,不同的作用机制可能存在不同的耐药机制,其中哪一种发挥了主要作用尚不明确.文章对利妥昔单抗ADCC作用机制中可能存在的影响疗效的因素进行综述. Rituximab,a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20,comparing with chemotherapy has significantly improved the treatment outcome of all subgroups of B-cell lymphoma patients.However,not all patients respond to rituximab plus chemotherapy or relapse in a short time after response,which suggests the existence of resistance mechanisms.Antibody-dependent cell-mediated cytotoxicity （ADCC） is one of the main mechanisms of rituximab,so any abnormalities in ADCC pathway may affect the efficacy of rituximab.With the widely application of rituximab,its resistance mechanisms are attracting more attention.This review will summarize the factors within ADCC pathway that may affect the antitumor effect of rituximab.
作者 金璿(综述) 宋玉琴(审校) 朱军(审校)
机构地区 北京大学第一医院肿瘤化疗科 北京大学肿瘤医院暨北京市肿瘤防治研究所淋巴肿瘤内科恶性肿瘤发病机制及转化研究教育部重点实验室
出处 《白血病．淋巴瘤》 CAS 2013年第11期697-700,共4页 Journal of Leukemia & Lymphoma
基金 国家自然科学基金（30973484）
关键词 淋巴瘤 非霍奇金 利妥昔单抗 耐药机制 抗体依赖细胞介导细胞毒作用 Lymphoma, non-Hodgkin＇s Rituximab Resistance mechanism Antibody-dependentcell-mediated cytotoxicity
分类号 R392.4 [医药卫生—免疫学]
  • 相关文献

参考文献28

  • 1Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R- CHOP study in the treatment of elderly patients with diffuse large B- cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2Q05, 23:4117-4126.
  • 2Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene, 2003, 22: 7359-7368.
  • 3Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Meal, 2000, 6: 443-446.
  • 4Eccles SA. Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger? Breast Cancer Res, 2001, 3: 86-90.
  • 5Cartron G, Daeheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 2002, 99: 754-758.
  • 6Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol, 2003, 21: 3940-3947.
  • 7Weng WK, Levy R. Gnentie polymorphism of the inhibitory IgG Fc receptor FegammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk Lymphoma, 2009, 50: 723-727.
  • 8Persky DO, Dornan D, Goldman BH, et al. Fc gamma recepto!" 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica, 2012, 97: 937-942.
  • 9Farag SS, Flinn IW, Modali R, et al. Fc gamma R 11I a and Fc gamma R ]I a polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood, 2004-, 103:1472-1474.
  • 10Carloni E, Palumbo GA, Oldani E, et al. FcgammaR IlI A and FcgammaR ]I A polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica, 2007, 92:1127-1130.

二级参考文献13

  • 1张文霞,郭军,林保和,孟松娘,王小沛,谢彦,郑文,张运涛,朱军.白细胞介素2增强利妥昔单抗介导的细胞毒杀伤效应机制研究[J].中华血液学杂志,2007,28(1):41-44. 被引量：1
  • 2Monton LM,Wang SS,Devesa SS,et al.Lymphoma incidence patterns by WHO subtype in United States,1992-2001.Blood,2006,107:265-276.
  • 3Coiffier B,Le page E,Briere J,et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma.N Engl J Med,2002,346:235-242.
  • 4Pfreundschuh M,Truemper L,Osterborg A,et al.CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:a randomised controlled trial by the MabThera International Trial (MInT) Group.The Lancet Oncol,2006,7:357-359.
  • 5Manches O,Lui G,Chaperot L,et al.In vivo mechanisms of action of rituximab on primary non-Hodgkin lymphomas.Blood,2003,101:949-954.
  • 6Cooper MA,Fehniger TA,Caligiuri MA.Human natural killer cells:a unique innate immunoregulatory role of the CD56dim subset.Blood,2001,97:3146-3151.
  • 7Cooper MA,Fehniger TA,Turner SC,et al.The biology of human natural killer-cell subsets.Trends Immunol,2001,22:633-640.
  • 8Feugier P,Van Hoof A,Sebban C,et al.Long-term results of the RCHOP study in the treatment of elderly patients with diffuse large Bcell lymphoma:a study by the Groupe d'Etude des Lymphomas del'Aduhe.J Clin Oncol,2005,23:4117-4126.
  • 9Pfrundschuh M,Trumper L,Gill D,et al.Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas:results of the NHL2B1 trial of the DSHNHL.Blood,2004,104:626-627.
  • 10Gluck WL,Hum D,Yuen A,et al.Phase Ⅰ studies of interleukin (IL)-2and rituximab in B-cell non-Hodgkin's lymphoma:IL-2 mediated natural killer cell expansion correlations with clinical response.Clin Cancer Res,2004,10:2253-2264.

共引文献2

白血病．淋巴瘤
2013年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部